F-1: Psyence Biomedical Files for Resale of Over 10 Million Common Shares

Psyence Biomedical seeks to register the resale of over 10 million common shares by existing securityholders, including shares related to debt settlements, make-whole obligations, and a purchase agreement with White Lion Capital.

Summary

• Psyence Biomedical has filed a registration statement for the potential offer and sale of 10,882,355 common shares.
• The shares are to be sold by existing securityholders.
• These include 182,323 shares issued to the Harraden Funds, 337,750 shares to Psyence Group Inc (PGI) for make-whole obligations, 257,021 shares to PGI for Psylabs Purchase Agreement obligations, 43,080 shares to Newcourt SPAC Sponsor LLC for debt settlement, 62,181 shares to Newcourt SPAC Sponsor LLC for make-whole obligations, and up to 10,000,000 shares issuable to White Lion Capital, LLC under a purchase agreement.
• The company will not receive any proceeds from the sale of shares by the selling securityholders, except that it may receive up to $18,612,403 from the sale of Common Shares to White Lion pursuant to the White Lion Purchase Agreement after the date of this prospectus.
• The company has also implemented a 75-to-1 reverse stock split, effective November 26, 2024.

Sentiment

Score: 4

Explanation: The document is largely factual, outlining the registration of shares for resale. The sentiment is neutral, with some positive aspects (potential funding from White Lion) balanced by negative aspects (risks related to share dilution and the company's financial position).

Positives

• The termination of the Harraden Transaction Documents simplifies the company's capital structure.
• The company has access to a $25 million equity line of credit with White Lion Capital, providing potential funding for future operations.

Negatives

• The securities being offered represent a significant percentage of the number of outstanding Common Shares, and the sales of such shares, or the perception that these sales could occur, could depress the market price of our Common Shares and could impair our ability to raise capital through the sale of additional equity securities.

Risks

• Sales of Common Shares being offered by this prospectus represent vastly more than the number of our outstanding Common Shares, and the sales of such Common Shares, or the perception that those sales might occur, could depress the market price of our Common Shares and could impair our ability to raise capital through the sale of additional equity securities.
• The company has incurred significant losses since inception and expects to incur significant losses for the foreseeable future.
• The company requires substantial additional capital to finance its operations, and if it is unable to raise such capital when needed or on acceptable terms, it may be forced to delay, reduce, and/or eliminate one or more of its development programs or future commercialization efforts.
• The company's ability to develop and maintain effective internal controls is a risk factor.

Future Outlook

The company believes that the cash provided in the PIPE Financing, together with existing cash, will be sufficient to fund operations beyond 12 months following the Closing Date, but may need to seek additional funds sooner than planned.

Industry Context

The announcement reflects the ongoing activity in the biotechnology sector, particularly among companies pursuing novel therapies and requiring capital to fund clinical trials and operations.

Comparison to Industry Standards

• The reliance on external funding through equity lines of credit and convertible notes is a common practice among clinical-stage biotechnology companies, especially those without current revenue streams.
• Comparable companies in the psychedelic medicine space, such as Atai Life Sciences and Mind Medicine (MindMed), also utilize a mix of equity and debt financing to advance their clinical programs.
• The high rate of failure in clinical trials is a well-known industry challenge, and Psyence's focus on a specific indication (AjD in palliative care) may offer a more targeted approach compared to companies with broader pipelines.

Related Party Transactions

• The Corporation issued an unsecured convertible promissory note to PGI in the principal amount of $1,610,657.
• NCAC issued an unsecured convertible promissory note to the Sponsor in the principal amount of $1,615,501.
• The Company entered into swap agreements with the Sponsor and PGI to settle the promissory notes by issuing Common Shares.
• The Company issued 257,021 Common Shares to PGI pursuant to its make-whole obligations under the Psylabs Purchase Agreement Addendum.

Stakeholder Impact

• The sales of Common Shares being offered by this prospectus represent vastly more than the number of our outstanding Common Shares, and the sales of such Common Shares, or the perception that those sales might occur, could depress the market price of our Common Shares and could impair our ability to raise capital through the sale of additional equity securities.

Next Steps

• The selling securityholders may sell or otherwise dispose of the Common Shares described in this prospectus in a number of different ways and at varying prices.
• The company intends to actively monitor its MVLS and MVPHS and will evaluate available options to regain compliance with the Nasdaq continued listing standards.
• The Company expects to demonstrate compliance with all the applicable requirements for continued listing on The Nasdaq Capital Market within the Panels extension.

Key Dates

Keywords

Common Shares, Resale, Registration Statement, White Lion Capital, Debt Settlement, Make-Whole Obligations, Psyence Biomedical, Shares